Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of IBI302 in neovascular age-related macular degeneration; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• IBI302

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: ACTIVE_NOT_RECRUITING